- Home
- FSP vs KPTI Comparison
FSP vs KPTI Comparison
Compare FSP & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSP
- KPTI
- Stock Information
- Founded
- FSP 1981
- KPTI 2008
- Country
- FSP United States
- KPTI United States
- Employees
- FSP N/A
- KPTI N/A
- Industry
- FSP Real Estate Investment Trusts
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- FSP Real Estate
- KPTI Health Care
- Exchange
- FSP Nasdaq
- KPTI Nasdaq
- Market Cap
- FSP 120.3M
- KPTI 102.4M
- IPO Year
- FSP N/A
- KPTI 2013
- Fundamental
- Price
- FSP $1.10
- KPTI $5.36
- Analyst Decision
- FSP
- KPTI Strong Buy
- Analyst Count
- FSP 0
- KPTI 6
- Target Price
- FSP N/A
- KPTI $22.17
- AVG Volume (30 Days)
- FSP 807.5K
- KPTI 126.1K
- Earning Date
- FSP 10-28-2025
- KPTI 11-03-2025
- Dividend Yield
- FSP 3.64%
- KPTI N/A
- EPS Growth
- FSP N/A
- KPTI N/A
- EPS
- FSP N/A
- KPTI N/A
- Revenue
- FSP $109,497,000.00
- KPTI $142,530,000.00
- Revenue This Year
- FSP $4.36
- KPTI $4.87
- Revenue Next Year
- FSP $0.81
- KPTI $9.20
- P/E Ratio
- FSP N/A
- KPTI N/A
- Revenue Growth
- FSP N/A
- KPTI N/A
- 52 Week Low
- FSP $1.07
- KPTI $3.51
- 52 Week High
- FSP $2.21
- KPTI $14.24
- Technical
- Relative Strength Index (RSI)
- FSP 22.82
- KPTI 43.33
- Support Level
- FSP $1.39
- KPTI $5.01
- Resistance Level
- FSP $1.18
- KPTI $5.71
- Average True Range (ATR)
- FSP 0.06
- KPTI 0.37
- MACD
- FSP -0.00
- KPTI -0.04
- Stochastic Oscillator
- FSP 7.41
- KPTI 30.82
About FSP Franklin Street Properties Corp.
Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The company's operations include rental income from real estate leasing, interest income from secured loans made on office properties, property dispositions, and fee income from asset/property management and development. Franklin Street markets Atlanta, Dallas, Denver, Houston, and Minneapolis.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.